ARDB—Antibiotic Resistance Genes Database by Liu, Bo & Pop, Mihai
Published online 2 October 2008 Nucleic Acids Research, 2009, Vol. 37, Database issue D443–D447
doi:10.1093/nar/gkn656
ARDB—Antibiotic Resistance Genes Database
Bo Liu
1 and Mihai Pop
1,2,*
1Center for Bioinformatics and Computational Biology and
2Department of Computer Science, University of
Maryland, College Park, MD 20742, USA
Received August 14, 2008; Revised September 15, 2008; Accepted September 16, 2008
ABSTRACT
The treatment of infections is increasingly compro-
mised by the ability of bacteria to develop resis-
tance to antibiotics through mutations or through
the acquisition of resistance genes. Antibiotic resis-
tance genes also have the potential to be used for
bio-terror purposes through genetically modified
organisms. In order to facilitate the identification
and characterization of these genes, we have cre-
ated a manually curated database—the Antibiotic
Resistance Genes Database (ARDB)—unifying
most of the publicly available information on anti-
biotic resistance. Each gene and resistance type is
annotated with rich information, including resis-
tance profile, mechanism of action, ontology, COG
and CDD annotations, as well as external links to
sequence and protein databases. Our database
also supports sequence similarity searches and
implements an initial version of a tool for character-
izing common mutations that confer antibiotic resis-
tance. The information we provide can be used as
compendium of antibiotic resistance factors as well
as to identify the resistance genes of newly
sequenced genes, genomes, or metagenomes.
Currently, ARDB contains resistance information
for 13293 genes, 377 types, 257 antibiotics, 632
genomes, 933 species and 124 genera. ARDB is
available at http://ardb.cbcb.umd.edu/.
INTRODUCTION
The discovery of penicillin in 1928 by Alexander Fleming
has revolutionized the treatment of bacterial infections.
The large-scale use of antibiotics, however, has also led
to an increase in the number of microbes that can resist
treatment. Drug resistant bacteria are an increasing threat
to public health, as highlighted by a recent estimate that in
the US methicillin-resistant Staphylococcus aureus
(MRSA) may contribute to more deaths than HIV (1).
Methicillin-resistant strains of S. aureus were initially
documented in the 1960s (2) and have been associated
with higher mortality rates (3,4) than their drug-sensitive
counterparts. Similar challenges are posed by the emer-
gence of multidrug- and extensively-drug resistant tuber-
culosis (MDR-TB and XDR-TB, respectively) (5,6).
Antibiotic resistance can result from large genomic
changes, such as the acquisition of entire plasmids or
mobile elements encoding resistance factors. Recent
studies are, however, revealing the important role small
mutations play in the evolution of resistance. For exam-
ple, only 35 point-mutations distinguish a vancomycin-
resistant strain of S. aureus from its sensitive counterpart,
and these mutations evolved in just 3 months within an
infected patient (7). Furthermore, antibiotic resistance
genes have the potential to be used for bioterrorism pur-
poses through genetically modiﬁed organisms. These fac-
tors emphasize the urgent need for a better understanding
of the mechanisms through which bacteria develop
resistance, as well as for the development of new techni-
ques for the rapid identiﬁcation of resistance factors. The
database presented in this article provides a ﬁrst compo-
nent of an informatics infrastructure aimed at enabling
such studies.
Several mechanisms have been characterized through
which bacteria become resistant to antibiotics (8): (i)
the production of enzymes that digest/metabolize the anti-
biotic; (ii) eﬄux pumps that eliminate the drug from the
cell; (iii) modiﬁcations to the cellular target of the anti-
biotic that prevent binding; (iv) activation of an
alternate pathway that bypasses drug action; and (v) par-
ticularly for gram-negative bacteria, down-regulation
or elimination of transmembrane porins through
which drugs enter the cell (9). The annotation information
commonly associated with genes deposited in public data-
bases is insuﬃciently detailed for representing this variety
of resistance mechanisms and the additional meta-
information relevant in this context. Speciﬁcally, each
resistance gene is associated with a resistance proﬁle
(set of antibiotics or classes of antibiotics targeted by
the gene), yet this information is usually not available.
Second, resistance often requires the cooperation of multi-
ple genes, usually within a same operon [e.g. vancomycin
resistance VanA operon requires seven genes (10)], while
most annotation information is targeted at individ-
ual genes. Finally, resistance frequently results from
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vidual gene (e.g. modiﬁcations of the drug target), infor-
mation incompatible with standard annotation
procedures. Consequently, specialized resources are neces-
sary for annotating and cataloging information related to
antibiotic resistance.
Several recent eﬀorts have been made to partially unify
this information, such as Antibiotic Resistance Genes
Online (ARGO) (11), MvirDB (12) and a compendium
of TEM b-lactamase genes at the Lahey Clinic (http://
www.lahey.org/Studies/). All, however, have limited func-
tionality. ARGO only contains part of b-lactamase,
vancomycin and tetracycline resistance genes. In addition,
it does not include rich annotation information such
as resistance proﬁle, mechanism of action, operon infor-
mation or gene sequence. Furthermore, many of the links
between ARGO and GenBank target incorrect records
(e.g. links to a genome instead of the relevant gene
record). MvirDB is a broad repository of virulence-
associated genes, including toxins, virulence factors and
antibiotic resistance. The latter information is simply
a replicate of the ARGO database. The Lahey Clinic
website is a comprehensive collection of TEM type
b-lactamases, which attempts to standardize the nomen-
clature for these genes. In addition to these special-
ized resources, antibiotic resistance information can be
extracted in a restricted manner from GenBank (13)
and SwissProt (14), databases that lack many important
types of information relevant in this domain.
To address the limitations of currently available public
resources, and to facilitate the identiﬁcation and charac-
terization of antibiotic resistance genes, we have created a
manually curated database [Antibiotic Resistance Genes
Database (ARDB)] unifying most of the publicly available
genes and related information. Our motivations in creat-
ing ARDB are (i) to provide a centralized compendium of
information on antibiotic resistance; (ii) to facilitate the
consistent annotation of resistance information in newly
sequenced organisms; and (iii) to facilitate the identiﬁca-
tion and characterization of new genes. We believe this
resource will be found useful by a broad range of scien-
tists, including microbiologists, clinicians and the bio-
defense research community.
DATABASE CONTENTS AND CONSTRUCTION
The diversity of antibiotic resistance genes, types and
mechanisms, combined with the fact that related informa-
tion, such as resistance proﬁle, is mostly ‘paper-bound’
made the construction of ARDB both diﬃcult and time-
consuming. To compile, conﬁrm and validate this collec-
tion of data, several textbooks and several hundred
journal articles were searched and summarized.
The majority of protein and nucleic acid sequences of
known antibiotic resistance genes were retrieved from the
NCBI nucleotide and protein databases and additional
sequences were retrieved from the Swiss-Prot database.
Genes were grouped into resistance types based on their
protein sequence similarity using the following approach.
First, the sequence of an experimentally conﬁrmed
representative was identiﬁed for every type of resistance,
based on literature searches and meta-information pro-
vided by the NCBI protein database. These representative
resistance genes were then used to ‘ﬁsh out’ additional
homologues using similarity searches against the NCBI
nr database. The similarity cutoﬀ was set at 80% unless
a diﬀerent value was recommended in the literature for a
speciﬁc resistance type. Using this approach we identiﬁed
13254 protein sequences putatively involved in antibiotic
resistance. We ﬁltered this set by removing vector
sequences, synthetic constructs and redundant genes,
resulting in a non-redundant set of 6206 proteins. This
set was further reﬁned by removing incomplete sequences,
thereby yielding a core set of 4554 antibiotic resistance
proteins. Each sequence was associated with correspond-
ing CDD, COG, ontology and source organism informa-
tion. Furthermore, the genes were grouped into resistance
types, corresponding to clusters of genes with similar resis-
tance proﬁles, operon membership and mechanism
of action. In addition, basic information about known
antibiotics was extracted from KEGG DRUG (15),
PubChem, PubMed MeSH database and the Chemical
Entities of Biological Interest (ChEBI) ontology.
Although ARDB is mainly targeted at antibiotic resis-
tance genes, 12 additional drug targets have also been
included into ARDB with relevant information [16S
rRNA (16), 23S rRNA, gyrA (17), gyrB, parC, parE,
rpoB, katG, pncA, embB, folP, dfr], whose modiﬁcation
has been shown to confer resistance.
The data ﬂow for the curation process is highlighted in
Figure 1. ARDB is implemented as a MySQL relational
database, and the corresponding schema is available on
our website. Access to this database is provided through a
CGI-based web interface.
ONTOLOGY INFORMATION
No comprehensive ontology is currently available
for annotating antibiotic resistance information. To facil-
itate the computational analysis of antibiotic resistance
information we have created a set of ontology terms
aimed at characterizing both the resistance proﬁle con-
ferred by a speciﬁc gene and its speciﬁc mechanism
of action. Speciﬁcally, for every antibiotic X, we have
created a set of ‘X resistance’ terms. Furthermore, we
classify several mechanisms of action, including
drug target modiﬁcation, replacement or protection,
drug enzymatic destruction and drug transport. Drug
transport is further subclassiﬁed into ATP-binding
cassette (ABC) drug eﬄux, major facilitator superfamily
(MFS) drug eﬄux, small multidrug resistance (SMR) drug
eﬄux and resistance-nodulation-cell division (RND)
drug eﬄux, following the terminology used in (18).
These terms are deﬁned within an Antibiotic Resistance
(AR) ontology and are associated with each record pres-
ent in our database. We are currently working with the
broader ontology community to further reﬁne this infor-
mation and integrate it within existing ontology develop-
ment eﬀorts.
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Users can access our database through a web interface at
http://ardb.cbcb.umd.edu. This interface provides several
modes of interaction as highlighted below.
Keyword searches
Simple keyword search is available at the top of each page
of ARDB website (Figure 2a), providing a quick means
for searching a speciﬁc object in our database (gene, type,
antibiotic, genome and genus) (Figure 2b and f). Users can
search all of the data, or narrow down the search to a
speciﬁc type of information. For example, users interested
in the molecular mechanisms of resistance to tetracycline
can search for the keyword ‘tetracycline’ within the
‘Resistance Type’ database. An advanced search function
is also available, allowing users to select from among the
available keywords associated with each database ﬁeld.
Similarity searches
BLAST. To help identify and annotate antibiotic resis-
tance genes, a BLAST interface is also provided. One or
more sequences can be provided to this interface in
a multi-FASTA ﬁle, corresponding to a set of gene
sequences. Furthermore, both nucleotide and amino-acid
sequences are accepted by our system. The results can be
visualized as standard BLAST output, however additional
displays are provided that are speciﬁc to antibiotic resis-
tance information. Our ‘ARDB annotation format’
groups individual BLAST hits according to resistance
type as inferred from the level of similarity to the genes
within the database associated with a speciﬁc type of resis-
tance (Figure 2c). A second view allows users to download
a tab-delimited spreadsheet summary of the antibiotic
resistance genes identiﬁed within the uploaded ﬁle.
RPSBLAST. In addition to BLAST we also provide an
RPSBLAST (19) interface relying on Position Speciﬁc
Scoring Matrix (PSSM) created from sequences associated
with each resistance type, using an approach similar to the
NCBI Conserved Domain Database (20). The output of
this interface is similar to that provided by the BLAST
interface mentioned above.
Polymorphism detection. Additionally, a mutation-speciﬁc
search function is provided to identify polymorphisms
previously characterized to confer resistance (Figure 2d).
For example, a G-C mutation at position 1058 of the
Escherichia coli 16S rRNA has been shown to confer resis-
tance to tetracycline (21). This information is extracted
from the detailed BLAST alignment between the query
sequence and a reference sequence in our database.
Currently this function is available for 12 genes
(16S rRNA, 23S rRNA, gyrA, gyrB, parC, parE, rpoB,
katG, pncA, embB, folP, dfr), and we expect to extend it
as more information becomes available in the literature.
Pre-annotatedinformation
The antibiotic resistance proﬁles of 632 complete bacterial
genomes have already been annotated and deposited
in ARDB allowing quick search. This information can
be conveniently extracted through keyword searches
against the ‘genome’ database, or through the ‘Genome
Resistance Proﬁles Comparison’ link from the front page.
The latter approach allows users to summarize and com-
pare the resistance proﬁles of multiple organisms present
in our database.
Browse
A ‘browse’ function is available that allows the users to
visualize several classes of antibiotic resistance genes,
grouped by their resistance proﬁle. This functionality
Figure 1. ARDB curation data ﬂow.
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macrolide–lincosamide–streptogramin B, multidrug trans-
porter, tetracycline and vancomycin resistance (Figure 2e).
Submission
In order to facilitate community-driven reﬁnement of our
database we provide an interface through which users
can submit information about novel resistance genes.
This interface captures several types of information not
commonly available in other databases [Minimum
Inhibitory Concentration (MIC), resistance type, ontol-
ogy, citation information, etc.]. Furthermore we provide
a simple ﬁle format and upload functionality to facilitate
the submission of information for multiple genes. The
information received will be vetted and inserted into the
database. We are also planning to develop an interface
that allows community-deposited information to be
Figure 2. Sample web pages from ARDB. (a) Front page, (b) resistance type, (c) blast result, (d) mutation annotation, (e) browse and (f) genome
information.
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pending additional manual curation.
CONCLUSION AND DISCUSSION
The database described in this article, ARDB, uniﬁes most
of the publicly available antibiotic resistance genes and
provides a reliable annotation service to researchers inves-
tigating the molecular basis for resistance in bacteria.
Because of the large diversity and the rapid identiﬁcation
of new resistance genes, the current version of ARDB is
just a ﬁrst catalog of currently available information, and
will continue to be updated over the coming months and
years. We plan to coordinate our development eﬀorts with
researchers actively involved in antibiotic resistance
research as well as with the developers of biological ontol-
ogies and of databases storing related information
(such as virulence factors or toxins). As part of these
eﬀorts we aim to reﬁne the structure of our database,
better determine the types of information stored and iden-
tify additional requirements for the user interface. Future
eﬀorts will also target the development of new approaches
for cataloguing and characterizing polymorphisms corre-
lated with resistance, as well as for annotating changes to
cellular regulatory networks that underlie the mechanisms
of drug tolerance.
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